ArticleMolecular therapy. Nucleic acids2022
A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A2.
Article in Molecular therapy. Nucleic acids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.Journal of nanobiotechnology · 2026Article
- Strategies, Challenges and Application Prospects for Exosome Engineering Modifications in Tumor Targeted Therapeutics.International journal of nanomedicine · 2026Review
- Artificial Intelligence-Based In Silico Evaluation of the Pharmacological Potential and In Vitro Anti-Malignancy Effect in the Human Glioblastoma Cell Line of the Hydrate of the Coumarin Compound Meranzin Originating From the Edible Macroalga (Food science & nutrition · 2026Article
- Aptamer-Based Biosensors for Rapid Detection and Early Warning of Food Contaminants: From Selection to Field Applications.Molecules (Basel, Switzerland) · 2025Review
- Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer.Cellular and molecular bioengineering · 2025Article
- Review
- ANXA2 in cancer: aberrant regulation of tumour cell apoptosis and its immune interactions.Cell death discovery · 2025Review
- Revolutionizing tumor diagnosis and treatment: the promise of DNA nanotechnology.Frontiers in immunology · 2025Review
- Targeting cancer stem cells by TPA leads to inhibition of refractory sarcoma and extended overall survival.Molecular therapy. Oncology · 2024Article
- Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications.Journal, genetic engineering & biotechnology · 2024Review
- Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells.Materials today. Bio · 2023Review
- CASZ1 promotes migration, invasion, and metastasis of lung cancer cells by controlling expression of ITGAV.American journal of cancer research · 2023Article
- Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of death worldwide. Cancer stem cells (CSCs) are the underlying reason for tumor recurrence, progression, and therapeutic resistance. Aptamers are synthetic single-stranded oligonucleotides that can specifically bind to various molecular targets. Here, we aim to develop an effective aptamer-based biomarker and therapeutic tool that targets CSCs for cancer therapy. We perform whole-cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) to screen DNA aptamers that specifically bound to lung CSCs, modeled by E-cadherin-silenced A549 cells. We develop a CSC-specific aptamer (AP-9R) specifically recognizing lung CSCs with high affinity and identify Annexin A2, a Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.